Triple drug therapy for advanced colorectal cancer after prior treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that has spread or cannot be removed by surgery, and it has not responded to at least two prior chemotherapy treatments.
- Your tumor type is 'microsatellite stable' (MSS) or 'mismatch repair proficient' (pMMR) — this is a lab test result you can ask your doctor about.
- You are physically able to care for yourself (up and about) — this is a score of 0-1 on a standard scale.
- You have not had any other cancer in the last 5 years, except for certain skin cancers.
- You have not previously received immunotherapy drugs like PD-1/PD-L1 inhibitors.
- You do not have an active autoimmune disease that requires treatment, and you are not currently on strong blood thinners.
- You are willing to provide a tumor tissue sample for testing, either from a past biopsy or by having a new one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.